Compare AbCellera Biologics Inc (ABCL) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Nasdaq Inc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Nasdaq Inc trades at $85.15 (market cap $48.88B). The key difference: Nasdaq Inc is far larger — about 20.8× AbCellera Biologics Inc's market cap, and Nasdaq Inc pays a 1.3% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NDAQ | |
|---|---|---|
Market Cap | $2.35B | $48.88B |
Sector | Health | Financials |
52-Week High | $8.12 | $100.98 |
52-Week Low | $2.78 | $76.85 |
Enterprise Value | $1.99B | $55.94B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Nasdaq (NDAQ) trades at $86.43, up 2.09% with strong fundamental performance including 2025 revenue of $8.26B and net income of $1.79B. The stock shows bullish technical signals with support at $83 and resistance at $86, while maintaining consistent earnings beats in recent quarters. Recent news highlights Nasdaq's record trading volumes and strategic expansions.
Outlook remains positive with analyst consensus target of $103 (19% upside), though risks include market volatility sensitivity and competitive pressures. The company's dominant exchange position and growing IPO pipeline provide solid growth foundation for investors seeking financial services exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
